ibrutinib + ofatumumab

Ibrutinib + ofatumumab is a combination therapy investigated for the treatment of B-cell malignancies, particularly chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The regimen combines **ibrutinib**, an oral small molecule that covalently inhibits Bruton's tyrosine kinase (BTK), with **ofatumumab**, a human monoclonal antibody targeting the CD20 antigen on B-cells. The rationale for this combination is based on their complementary mechanisms: ibrutinib inhibits B-cell receptor signaling and mobilizes malignant cells from tissue compartments into the peripheral blood, where the anti-CD20 antibody ofatumumab can more effectively clear them via complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). Clinical trials, including Phase 1b/2 and Phase 2 studies, have evaluated various administration sequences (such as ibrutinib lead-in or consolidation strategies) to optimize response rates and durability in both relapsed/refractory and treatment-naïve patients.

Other names

PCI-32765 + ofatumumab